These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 35716043)

  • 21. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.
    Uson Junior PLS; Borad MJ
    Semin Liver Dis; 2023 May; 43(2):218-225. PubMed ID: 36882151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
    Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
    JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
    Vatankhah F; Salimi N; Khalaji A; Baradaran B
    Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The roles of epigenetic regulation in cholangiocarcinogenesis.
    Zhong B; Liao Q; Wang X; Wang X; Zhang J
    Biomed Pharmacother; 2023 Oct; 166():115290. PubMed ID: 37557012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach.
    Venkatraman S; Balasubramanian B; Pongchaikul P; Tohtong R; Chutipongtanate S
    Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
    Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
    Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
    Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
    J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
    Cao Z; Zeng L; Wang Z; Wen X; Zhang J
    Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
    Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Increased Chromosome 7 Copy Number in Endoscopic Bile Duct Biopsy Specimens Is Predictive of a Poor Prognosis in Cholangiocarcinoma.
    Kato A; Naitoh I; Miyabe K; Hayashi K; Yoshida M; Hori Y; Natsume M; Jinno N; Asano G; Kato H; Kuno T; Takahashi S; Kataoka H
    Dig Dis Sci; 2018 Dec; 63(12):3376-3381. PubMed ID: 30206756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities.
    Høgdall D; O'Rourke CJ; Andersen JB
    Adv Cancer Res; 2022; 156():343-366. PubMed ID: 35961705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
    Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
    Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.